Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

Ilaria Galgania GSK, Siena, ItalyCorrespondence[email protected]

https://orcid.org/0000-0001-6315-4259 View further author information

Airi Põderb The Clinical Research Center, Tartu, EstoniaView further author information

Rain Jõgic The Lung Clinic, Tartu University Hospital, Tartu, EstoniaView further author information

Veli-Jukka Anttilad Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital and Helsinki University, Helsinki, FinlandView further author information

Stefano Millerie Centro Ricerche Cliniche di Verona Srl, Verona, ItalyView further author information

Alberto M. Borobiaf Clinical Pharmacology Department, La Paz University Hospital, IdiPAZ, Madrid, Spain;g School of Medicine, Autonomous University of Madrid, Madrid, Spain;h Spanish Clinical Research Network – SCReN, Madrid, Spain;i Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, SpainView further author information

Odile Launayj Université Paris Cité, Paris, France;k Inserm CIC 1417, F-CRIN I-REIVAC, Paris, France;l Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, FranceView further author information

Marco Testaa GSK, Siena, ItalyView further author information

Daniela Casulaa GSK, Siena, ItalyView further author information

Luca Grassanoa GSK, Siena, ItalyView further author information

Annaelisa Tasciottia GSK, Siena, ItalyView further author information

Marie Dozotm GSK, Rixensart, BelgiumView further author information

Ashwani K. Aroran GSK, Wavre, BelgiumView further author information

show all